AR067877A1 - Compuestos de pirimidina - Google Patents

Compuestos de pirimidina

Info

Publication number
AR067877A1
AR067877A1 ARP080103456A ARP080103456A AR067877A1 AR 067877 A1 AR067877 A1 AR 067877A1 AR P080103456 A ARP080103456 A AR P080103456A AR P080103456 A ARP080103456 A AR P080103456A AR 067877 A1 AR067877 A1 AR 067877A1
Authority
AR
Argentina
Prior art keywords
co2r3
coor3
hal
denotes
nr3con
Prior art date
Application number
ARP080103456A
Other languages
English (en)
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of AR067877A1 publication Critical patent/AR067877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos son utiles, por ejemplo, en el tratamiento de trastornos autoinmunes, como, por ejemplo, la esclerosis multiple. Reivindicacion 1: Compuestos de acuerdo con la Formula (1) en donde: X es NRaRb,.SRb o Hal, Ra es H o A, Rb es A, A es alquilo lineal o ramificado que posee 1 a 12 átomos de carbono, en donde uno o más, con preferencia 1 a 7 átomos de H se pueden reemplazar por Hal, OR3, COOR3, CN o N(R3)2 y en donde uno o más, con preferencia 1 a 7 grupos CH2 no adyacentes se pueden reemplazar por O, NR3, S o SO2 y/o por grupos -CH=CH-, o denota cicloalquilo o cicloalquilalquileno que posee 3-7 átomos de C anulares; Hal es F, Cl, Br o I, W es C=O, C=S, SO2 o SO, Q es NR3, -O- o -S-, R es H, A, Ar, Het, Ar denota un anillo carbocíclico monocíclico o bicíclico, saturado, insaturado o aromático que posee 6 a 14 átomos de carbono, que puede estar no sustituido o monosustituido, disustituido o trisustituido por Hal, A, OR3, -[C(R3)2]n-OR3, N(R3)2, -[C(R3)2]n-N(R3)2, NO2, CN, COOR3, CF3, OCF3, CON(R3)2, NR3COA, NR3CON(R3)2, -[C(R3)2]n-, Het, -[C(R3)2]n-Ar, -[C(R3)2]n-cicloalkil, -[C(R3)2]n-, CON(R3)2, -[C(R3)2]n-COOR3, -[C(R3)2]-NR3-[C(R3)2]-CO2R3, -[C(R3)2]n-NR3-[C(R3)2]n-OR3, -SO2-[C(R3)2]n-CO2R3, -SO2- -N(R3)2-[C(R3)2]n-CO2R3, -[C(R3)2]-SO2-[C(R3)2]-CO2R3, -SO2-, [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -SO2-, [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -[C(R3)2]n-SO2-, [C(R3)2]n-OR3, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, SO2N(R3)A, SOA, SONR3A, o SO2A, y/o -O[C(R3)2]n-COOR3, Het denota un anillo heterocíclico, nomocíclico o bicíclico, saturado, insaturado o aromático que posee 1 a 4 átomos de N, O y/o S que puede estar no sustituido o monosustituido, disustituido o trisustituido por Hal, A, OR3, -[C(R3)2]n-OR3, N(R3)2, -[C(R3)2)n-N(R3)2, NO2, CN, COOR3, CF3, OCF3, CON(R3)2, NR3COA, NR3CON(R3)2, -[C(R3)2]n-Het, -[C(R3)2]n-Ar, -[C(R3)2]n-cicloalkil, -[C(R3)2]n-CON(R3)2, -[C(R3)2]n-COOR3, -[C(R3)2]-NR3-[C(R3)2]n-CO2R3, -[C(R3)2]-NR3-[C(R3)2]n-OR3, -SO2-[C(R3)2]n-CO2R3, -SO2-, N(R3)2-[C(R3)2]n-CO2R3, -[C(R3)2]n-SO2-[C(R3)2]n-CO2R3, -SO2- [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -[C(R3)2]n-SO2-, [C(R3)2]n-OR3, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, SO2N(R3)A, SOA, SONR3A, o SO2A, y/o -O[C(R3)2]-COOR3, R1 denota A o H, R2 denota H, A o HAL R3 es H o A n es 0, 1, 2, 3, 4, 5, 6, 7 o 8, y sus derivados, solvatos, tautomeros, sales y estereoisomeros farmacéuticamente aceptables, con inclusion de sus mezclas en todas las relaciones.
ARP080103456A 2007-08-08 2008-08-07 Compuestos de pirimidina AR067877A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113992 2007-08-08
US96486407P 2007-08-15 2007-08-15

Publications (1)

Publication Number Publication Date
AR067877A1 true AR067877A1 (es) 2009-10-28

Family

ID=38985492

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103456A AR067877A1 (es) 2007-08-08 2008-08-07 Compuestos de pirimidina

Country Status (15)

Country Link
US (2) US8399448B2 (es)
EP (1) EP2183224B1 (es)
JP (1) JP5508265B2 (es)
KR (1) KR20100051849A (es)
CN (1) CN101790519B (es)
AR (1) AR067877A1 (es)
AU (1) AU2008285722B2 (es)
BR (1) BRPI0814975A2 (es)
CA (1) CA2696565C (es)
EA (1) EA201070238A1 (es)
ES (1) ES2445405T3 (es)
IL (1) IL203578A (es)
MX (1) MX2010001446A (es)
WO (1) WO2009019167A1 (es)
ZA (1) ZA201000585B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008302746B2 (en) * 2007-09-20 2014-07-03 Amgen Inc. 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders
MX354134B (es) 2008-07-23 2018-02-14 Arena Pharm Inc Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias.
CA2733671C (en) 2008-08-27 2018-01-02 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
JP2013508385A (ja) 2009-10-23 2013-03-07 アラーガン インコーポレイテッド 治療上有用な、受容体修飾薬としてのクマリン化合物
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2547662A4 (en) * 2010-03-17 2013-10-02 Glaxo Group Ltd PYRIMIDINE DERIVATIVES FOR USE AS AGONISTS OF SPHINGOSIN 1-PHOSPHATE 1 (S1P1) RECEPTORS
SG194184A1 (en) * 2011-04-14 2013-11-29 Allergan Inc Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20140235592A1 (en) * 2013-02-21 2014-08-21 Allergan, Inc. Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
CN103408501B (zh) * 2013-08-14 2016-03-09 合肥医工医药有限公司 苄基嘧啶衍生物、其制备方法及其医药用途
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
KR20160115933A (ko) * 2014-01-10 2016-10-06 오리진 디스커버리 테크놀로지스 리미티드 Irak4 억제제로서의 인다졸 화합물
SG10201811204RA (en) 2014-01-13 2019-01-30 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
KR101499007B1 (ko) * 2014-04-24 2015-03-05 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
KR102633530B1 (ko) 2017-03-31 2024-02-02 오리진 온콜로지 리미티드 혈액 장애를 치료하기 위한 화합물 및 조성물
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
WO2019089580A1 (en) 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders
PL3755703T3 (pl) 2018-02-20 2022-11-07 Incyte Corporation Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
GB202213310D0 (en) * 2022-09-12 2022-10-26 Benevolentai Cambridge Ltd New compounds and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1115707T3 (da) * 1998-09-25 2004-03-01 Astrazeneca Ab Benzamidderivater og deres anvendelse som cytokininhibitorer
WO2002096903A2 (fr) * 2001-05-28 2002-12-05 Aventis Pharma S.A. Derives chimiques et leur application comme agent antitelomerase
WO2003105840A2 (en) 2002-06-17 2003-12-24 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
TW200524880A (en) 2003-10-21 2005-08-01 Sankyo Co Pyrimidine compounds
EP1694659B8 (en) 2003-12-19 2008-10-08 Schering Corporation Thiadiazoles as cxc- and cc- chemokine receptor ligands
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa

Also Published As

Publication number Publication date
WO2009019167A1 (en) 2009-02-12
EA201070238A1 (ru) 2010-08-30
ZA201000585B (en) 2011-04-28
CN101790519A (zh) 2010-07-28
US8399448B2 (en) 2013-03-19
JP2010535734A (ja) 2010-11-25
EP2183224A1 (en) 2010-05-12
IL203578A (en) 2014-02-27
CN101790519B (zh) 2013-10-16
CA2696565A1 (en) 2009-02-12
JP5508265B2 (ja) 2014-05-28
ES2445405T3 (es) 2014-03-03
MX2010001446A (es) 2010-03-01
BRPI0814975A2 (pt) 2015-02-03
KR20100051849A (ko) 2010-05-18
EP2183224B1 (en) 2013-11-06
AU2008285722B2 (en) 2013-06-20
US9150519B2 (en) 2015-10-06
AU2008285722A1 (en) 2009-02-12
CA2696565C (en) 2017-02-14
US20130109669A1 (en) 2013-05-02
US20100210619A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
AR067877A1 (es) Compuestos de pirimidina
AR068731A1 (es) Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas.
AR076187A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen
AR076984A1 (es) Derivados de pirazol oxadiazol
AR074700A1 (es) Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
UY26727A1 (es) Derivados de tropano útiles en terapia
AR053569A1 (es) Derivados de pirazol
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
AR071285A1 (es) Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos.
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR066972A1 (es) Derivados azapeptidicos
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
AR075394A1 (es) Derivados del acido fenoxiacetico, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades inflamatorias,alergicas y neurodegenerativas.
AR053341A1 (es) Derivados azol triciclicos su fabricacion y uso como agentes farmaceuticos
PE20050292A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos
AR079997A1 (es) Derivados de acido carboxilico de oxazolo[5,4-d]pirimidinas utiles en el tratamiento del sindrome del pie diabetico(dfs), composiciones farmaceuticas que los contienen y metodo de preparacion de los mismos.
AR071790A1 (es) Derivados de n-(2-amino-fenil)-acrilamidas, utiles como agentes antitumorales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal